Fabrication, Characterization, and Pharmacokinetics of Phospholipid-Based Naturosomal Nanocarriers for Enhanced Oral Solubility and Bioavailability of Naringin

IF 3.4 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Vijay Metkari, Rohit Shah, Nitin Salunkhe, Shailendra Gurav
{"title":"Fabrication, Characterization, and Pharmacokinetics of Phospholipid-Based Naturosomal Nanocarriers for Enhanced Oral Solubility and Bioavailability of Naringin","authors":"Vijay Metkari,&nbsp;Rohit Shah,&nbsp;Nitin Salunkhe,&nbsp;Shailendra Gurav","doi":"10.1208/s12249-025-03047-1","DOIUrl":null,"url":null,"abstract":"<div><p>This study hypothesizes that phospholipid-based naturosoomal nanocarriers can significantly enhance the oral solubility and bioavailability of naringin (NARNs) by improving its absorption and pharmacokinetic profile. The NARNs were prepared using solvent evaporation techniques employing a quality-by-design approach followed by physicochemical (UV–visible spectroscopy, FTIR, DSC, XRD, SEM, TEM, PS, ZP analysis), functional (EE, apparent solubility, <i>in-vitro</i> drug release study) characterization and pharmacokinetic investigation. NARNs showed 91.15 ± 1.40% EE, with 12-fold aqueous solubility than the pure drug, i.e., naringin (NAR). The size of the NARNs vesicles was between 150 and 300 nm, demonstrating the controlled vesicle size, whereas the zeta potential and polydispersity index were -32.2 mV and 0.524, respectively signifying the excellent stability and homogeneity of naturosomal suspension. The NARNs <i>in-vitro</i> dissolution data demonstrated a superior release profile (92.12%) compared to pure NAR (38.90%) and physical mixture (43.72%). The pharmacokinetic parameters of NARN in the rabbit showed promising results (T<sub>max</sub> = 2.0 h, C<sub>max</sub> = 1.76 ± 0.10 µg/mL, and AUC<sub>0-24</sub> = 14.22 ± 0.13 µg/mL h). Thus, overall results indicated that naturosomal drug delivery is a capable method for improving the drug release profile of NAR and oral bioavailability, reducing toxicity by minimizing dose size.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 2","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-025-03047-1.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS PharmSciTech","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1208/s12249-025-03047-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This study hypothesizes that phospholipid-based naturosoomal nanocarriers can significantly enhance the oral solubility and bioavailability of naringin (NARNs) by improving its absorption and pharmacokinetic profile. The NARNs were prepared using solvent evaporation techniques employing a quality-by-design approach followed by physicochemical (UV–visible spectroscopy, FTIR, DSC, XRD, SEM, TEM, PS, ZP analysis), functional (EE, apparent solubility, in-vitro drug release study) characterization and pharmacokinetic investigation. NARNs showed 91.15 ± 1.40% EE, with 12-fold aqueous solubility than the pure drug, i.e., naringin (NAR). The size of the NARNs vesicles was between 150 and 300 nm, demonstrating the controlled vesicle size, whereas the zeta potential and polydispersity index were -32.2 mV and 0.524, respectively signifying the excellent stability and homogeneity of naturosomal suspension. The NARNs in-vitro dissolution data demonstrated a superior release profile (92.12%) compared to pure NAR (38.90%) and physical mixture (43.72%). The pharmacokinetic parameters of NARN in the rabbit showed promising results (Tmax = 2.0 h, Cmax = 1.76 ± 0.10 µg/mL, and AUC0-24 = 14.22 ± 0.13 µg/mL h). Thus, overall results indicated that naturosomal drug delivery is a capable method for improving the drug release profile of NAR and oral bioavailability, reducing toxicity by minimizing dose size.

Graphical Abstract

提高柚皮苷口服溶解度和生物利用度的磷脂基天然体纳米载体的制备、表征和药代动力学研究
本研究假设基于磷脂的天然纳米载体可以通过改善柚皮苷的吸收和药代动力学特征,显著提高其口服溶解度和生物利用度。采用溶剂蒸发技术制备NARNs,采用质量设计方法,然后进行理化(紫外-可见光谱、FTIR、DSC、XRD、SEM、TEM、PS、ZP分析)、功能(EE、表观溶解度、体外药物释放研究)表征和药代动力学研究。NARNs的EE值为91.15±1.40%,水溶性为纯药物naringin (NAR)的12倍。NARNs的囊泡大小在150 ~ 300 nm之间,表明其囊泡大小可控,而zeta电位和多分散性指数分别为-32.2 mV和0.524,表明其具有良好的稳定性和均匀性。与纯NAR(38.90%)和物理混合物(43.72%)相比,NARNs的体外释放度为92.12%。在家兔体内的药代动力学参数(Tmax = 2.0 h, Cmax = 1.76±0.10µg/mL, AUC0-24 = 14.22±0.13µg/mL h)显示出令人满意的结果,表明自然体给药是改善NAR药物释放和口服生物利用度的有效方法,可通过减小给药剂量来降低毒性。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AAPS PharmSciTech
AAPS PharmSciTech 医学-药学
CiteScore
6.80
自引率
3.00%
发文量
264
审稿时长
2.4 months
期刊介绍: AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信